Literature DB >> 18696044

Can patients with type 2 diabetes be treated with 5'-AMP-activated protein kinase activators?

W W Winder1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18696044      PMCID： PMC2730159          DOI： 10.1007/s00125-008-1115-8

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  12 in total

1.  Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome.

Authors:  Barbara Cool; Bradley Zinker; William Chiou; Lemma Kifle; Ning Cao; Matthew Perham; Robert Dickinson; Andrew Adler; Gerard Gagne; Rajesh Iyengar; Gang Zhao; Kennan Marsh; Philip Kym; Paul Jung; Heidi S Camp; Ernst Frevert
Journal:  Cell Metab       Date:  2006-06       Impact factor: 27.287

2.  5-Aminoimidazole-4-carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice.

Authors:  X M Song; M Fiedler; D Galuska; J W Ryder; M Fernström; A V Chibalin; H Wallberg-Henriksson; J R Zierath
Journal:  Diabetologia       Date:  2002-01       Impact factor: 10.122

3.  Long-term AICAR administration and exercise prevents diabetes in ZDF rats.

Authors:  Rasmus Pold; Lasse S Jensen; Niels Jessen; Esben S Buhl; Ole Schmitz; Allan Flyvbjerg; Nobuharu Fujii; Laurie J Goodyear; Carsten F Gotfredsen; Christian L Brand; Sten Lund
Journal:  Diabetes       Date:  2005-04       Impact factor: 9.461

4.  5-aminoimidazole-4-carboxy-amide-1-beta-D-ribofuranoside treatment ameliorates hyperglycaemia and hyperinsulinaemia but not dyslipidaemia in KKAy-CETP mice.

Authors:  M Fiedler; J R Zierath; G Selén; H Wallberg-Henriksson; Y Liang; K S Sakariassen
Journal:  Diabetologia       Date:  2001-12       Impact factor: 10.122

5.  Chronic activation of 5'-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle.

Authors:  B F Holmes; E J Kurth-Kraczek; W W Winder
Journal:  J Appl Physiol (1985)       Date:  1999-11

Review 6.  AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes.

Authors:  W W Winder; D G Hardie
Journal:  Am J Physiol       Date:  1999-07

7.  AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle.

Authors:  G F Merrill; E J Kurth; D G Hardie; W W Winder
Journal:  Am J Physiol       Date:  1997-12

8.  Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats.

Authors:  R Bergeron; S F Previs; G W Cline; P Perret; R R Russell; L H Young; G I Shulman
Journal:  Diabetes       Date:  2001-05       Impact factor: 9.461

9.  5-aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside acutely stimulates skeletal muscle 2-deoxyglucose uptake in healthy men.

Authors:  Daniel J Cuthbertson; John A Babraj; Kirsteen J W Mustard; Mhairi C Towler; Kevin A Green; Henning Wackerhage; Graeme P Leese; Keith Baar; Michaela Thomason-Hughes; Calum Sutherland; D Grahame Hardie; Michael J Rennie
Journal:  Diabetes       Date:  2007-05-18       Impact factor: 9.461

10.  Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome.

Authors:  Esben S Buhl; Niels Jessen; Rasmus Pold; Thomas Ledet; Allan Flyvbjerg; Steen B Pedersen; Oluf Pedersen; Ole Schmitz; Sten Lund
Journal:  Diabetes       Date:  2002-07       Impact factor: 9.461
View more
  6 in total

1.  Novel protective mechanism of reducing renal cell damage in diabetes: Activation AMPK by AICAR increased NRF2/OGG1 proteins and reduced oxidative DNA damage.

Authors:  Samy L Habib; Anamika Yadav; Dawit Kidane; Robert H Weiss; Sitai Liang
Journal:  Cell Cycle       Date:  2016-09-09       Impact factor: 4.534

2.  High-glucose toxicity is mediated by AICAR-transformylase/IMP cyclohydrolase and mitigated by AMP-activated protein kinase in Caenorhabditis elegans.

Authors:  Christin Riedinger; Michael Mendler; Andrea Schlotterer; Thomas Fleming; Jürgen Okun; Hans-Peter Hammes; Stephan Herzig; Peter P Nawroth
Journal:  J Biol Chem       Date:  2018-02-02       Impact factor: 5.157

3.  Adenosine Monophosphate-Activated Protein Kinase (AMPK) as a New Target for Antidiabetic Drugs: A Review on Metabolic, Pharmacological and Chemical Considerations.

Authors:  Arie Gruzman; Gali Babai; Shlomo Sasson
Journal:  Rev Diabet Stud       Date:  2009-05-10

4.  Effects of intravenous AICAR (5-aminoimidazole-4-carboximide riboside) administration on insulin signaling and resistance in premature baboons, Papio sp.

Authors:  Cynthia L Blanco; Amalia Gastaldelli; Diana G Anzueto; Lauryn A Winter; Steven R Seidner; Donald C McCurnin; Hanyu Liang; Martin A Javors; Ralph A DeFronzo; Nicolas Musi
Journal:  PLoS One       Date:  2018-12-12       Impact factor: 3.240

5.  VASP increases hepatic fatty acid oxidation by activating AMPK in mice.

Authors:  Sanshiro Tateya; Norma Rizzo-De Leon; Priya Handa; Andrew M Cheng; Vicki Morgan-Stevenson; Kayoko Ogimoto; Jenny E Kanter; Karin E Bornfeldt; Guenter Daum; Alexander W Clowes; Alan Chait; Francis Kim
Journal:  Diabetes       Date:  2013-01-24       Impact factor: 9.461

6.  Chronic exposure to nicotine enhances insulin sensitivity through α7 nicotinic acetylcholine receptor-STAT3 pathway.

Authors:  Tian-Ying Xu; Ling-Ling Guo; Pei Wang; Jie Song; Ying-Ying Le; Benoit Viollet; Chao-Yu Miao
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.